PRISM BioView Dive: Recent Report Projects Global Biotech Equipment Market to Accelerate Toward $144Bn by 2030 – Here’s Who to Watch

The biotechnology equipment sector is entering a new era of growth and innovation, driven by breakthroughs in cell and gene therapy, automation, and data-driven manufacturing. According to a recent BCC Research report, the global biotech equipment market is projected to expand from $95.1 billion in 2025 to $143.9 billion by 2030, representing a compound annual growth rate (CAGR) of 8.6%.

This growth underscores a broader transformation within biotechnology itself—where next-generation manufacturing technologies, advanced analytics, and sustainability imperatives are redefining how therapeutics are developed and produced.

Investment Surge and the Next Wave of Equipment Demand

Increased R&D funding from governments, venture investors, and pharmaceutical companies is fueling rapid adoption of new equipment across research, diagnostics, and biomanufacturing facilities. With the global biotech market expected to reach $3.88 trillion by 2030 (CAGR 13.9%), the demand for high-precision, compliant, and scalable tools is rising across every segment of the life sciences ecosystem.

According to BCC Research, the largest equipment buyers remain pharmaceutical and biotech companies, reflecting their dominant role in bringing new therapies from concept to commercialization. North America currently accounts for 48% of total market share, followed by strong growth in Asia-Pacific driven by capacity expansion, government incentives, and lower manufacturing costs.

Trends Shaping Biotech Equipment:

In a recent report, PSG Biotech’s Michael Franco outlined the major forces influencing the adoption of next-generation biotech equipment across global manufacturing:

1. Single-Use Systems Redefining Bioprocessing

Single-use technologies (SUTs) have become a cornerstone of modern biomanufacturing. Adoption rates continue to climb as disposable bioreactors, pumps, and filtration systems reduce the risk of contamination and eliminate complex cleaning validations.

A BioPlan Associates survey found that 87% of biomanufacturers plan to expand their use of single-use systems. These systems allow flexible, multi-product manufacturing critical as biologics pipelines diversify.

However, environmental and waste management concerns persist. Manufacturers are tackling these issues through precision control systems that improve material efficiency and support recyclability, aiming to combine performance with sustainability.

2. Automation, AI, and Data Integration

Automation and artificial intelligence (AI) are becoming essential for operational excellence in biotech production. Integrated digital systems now enable real-time process control, predictive maintenance, and deviation reduction—capabilities that directly impact cost efficiency and quality.

A McKinsey & Company study found that applying advanced analytics in biotech manufacturing led to a 30–50% reduction in process deviations and a 25–40% increase in plant capacity.

Key innovations shaping this evolution include:

• Automated bioreactor control systems that adjust parameters dynamically.
• Smart pumps and sensors capable of self-regulation and remote diagnostics.
• AI-driven analytics to standardize production across global sites.

Companies are focusing on modular automation platforms—solutions that integrate seamlessly with existing infrastructure while ensuring regulatory compliance under cGMP standards.

3. Equipment for Cell and Gene Therapy (CGT)

The rise of cell and gene therapy has brought specialized manufacturing requirements that differ from traditional biologics. These therapies demand ultra-precise control over biological materials and highly sterile environments.

The global CGT manufacturing market is projected to surpass $20.2 billion by 2030, fueled by CRISPR and mRNA platform development. Equipment innovation is concentrated in:

• Custom single-use systems optimized for CGT applications.
• High-precision flow control for micro-volume dosing and mixing.
• Automated contamination monitoring systems ensuring sterility and consistency.

Scalability remains one of the biggest hurdles. To bridge the gap between small-batch clinical production and commercial-scale manufacturing, vendors are deploying scalable modular systems that preserve process integrity as output increases.

4. Flexibility, Scalability, and Modular Design

The future of biotech manufacturing is agile. Facilities must pivot rapidly between products, respond to global health crises, and manage decentralized production networks. A Pharma Manufacturing survey found that 70% of biotech firms are investing in modular or scalable systems to strengthen resilience and reduce dependency on single supply hubs.

This trend extends to decentralized biomanufacturing, which allows production closer to patient populations, an increasingly important model for gene and cell therapies and personalized medicine.

Companies are now delivering scalable pump and control systems designed to maintain precision and quality across variable batch sizes.

5. Market Segmentation and Regional Outlook

The biotech equipment market spans multiple categories, including analytical instruments, cell culture and separation systems, immunoassay platforms, and clinical chemistry analyzers. Analytical instruments are expected to remain dominant through 2030, supported by demand for precision testing in genomics, biomarker analysis, and quality assurance.

Regionally, the Asia-Pacific market is poised for the fastest growth due to infrastructure expansion, skilled workforce development, and regional collaborations. Meanwhile, Europe and North America continue to lead in regulatory alignment and early technology adoption.

6. Collaboration and Innovation as Industry Catalysts

Experts agree that cross-industry collaboration will define the next phase of biotech equipment development. Partnerships among manufacturers, biopharma firms, and regulators are crucial to overcoming cost, compliance, and data-sharing barriers.

“Collaboration is the cornerstone of progress,” said Michael Franco of PSG Biotech, noting that the companies leading the next decade will be those that combine automation, sustainability, and flexibility with open innovation models.

Outlook: The Decade of Smart, Sustainable Biomanufacturing

As biotechnology evolves toward data-rich, precision-driven manufacturing, the equipment market stands at the intersection of efficiency, sustainability, and scalability.

With single-use systems improving flexibility, automation enhancing reliability, and global investment accelerating adoption, biotech equipment will play a pivotal role in shaping the future of healthcare innovation.

For industry leaders, the key question is not whether to adapt—but how rapidly they can modernize to capture the opportunities ahead.

Biotech Equipment Emergers to Watch

As this market is poised for growth, companies in the space are emerging and continuing to evolve as new trends shape this industry. Some of these include:

Cryoport, Inc.

Cryoport, Inc. (NASDAQ: CYRX) is a specialized logistics and equipment company serving the global life sciences industry, with a focus on temperature-controlled supply chains. The company provides the infrastructure needed to safely store, transport, and monitor biological materials—including cell and gene therapies, vaccines, and other temperature-sensitive biologics—across clinical and commercial stages. Shares are up over ~20% YTD.

Seer, Inc.

Seer, Inc. (NASDAQ: SEER) is a life sciences technology company focused on advancing proteomics discovery through its Proteograph™ platform, which enables high-throughput sample preparation for mass spectrometry-based protein analysis. The company’s core offering transforms complex biological samples into data-rich outputs by combining proprietary nanoparticle-based assays with automation and software analysis. While the stock is down modestly on the year, shares have ran up ~13% in the last 6 months.

BioLife Solutions, Inc.

BioLife Solutions, Inc. (NASDAQ: BLFS) is a company specializing in equipment and consumables that support the manufacturing, storage, and transportation of biological and cell-based therapies. They design and supply products such as cryoprotectant media, controlled-rate freezers, automated thawing systems, and cold-chain logistics solutions—all intended to preserve the viability and integrity of sensitive biological samples across clinical and commercial settings. Shares have been steadily increasing this year with more momentum picking up in August, the stock is up ~8% YTD.